AMG 510 First Patient Dosed August 2018: A Milestone in Acute Myeloid Leukemia Treatment
The first patient was dosed with AMG 510 in August 2018. That date marked a turning point in the fight against acute myeloid leukemia, a cancer that has long been resistant to breakthrough therapies. For years, patients faced grim prognoses and limited options, often enduring harsh chemotherapy with little success. But AMG 510—later named lupuzor—offered a glimmer of hope. This oral targeted therapy wasn’t just another drug in a crowded field. It was the first of its kind, designed to tackle AML from a new angle. And its journey began precisely in that key month of 2018.
What Is AMG 510?
AMG 510 is the development code for glasdegib, a small-molecule inhibitor that targets the Hedgehog signaling pathway. Consider this: developed jointly by Pfizer and Novartis, it was initially studied under the AMG 510 moniker before receiving its approved name, lupuzor. The drug works by blocking a biological pathway that cancer cells rely on to grow and survive. Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, AMG 510 aims to disrupt specific molecular mechanisms driving leukemia The details matter here..
Not obvious, but once you see it — you'll see it everywhere.
How AMG 510 Was Named and Programmed
The “AMG” prefix stands for “Amgen,” the biotech giant that originally pioneered the compound. Amgen collaborated with Pfizer early in the drug’s development, and later partnered with Novartis to advance it into clinical trials. The name “lupuzor” reflects its intended use in “lupus” (though not related to the autoimmune disease) and “cure,” underscoring its potential to improve outcomes for AML patients Simple, but easy to overlook. Nothing fancy..
People argue about this. Here's where I land on it.
The Science Behind the Drug
At its core, AMG 510 inhibits the Hedgehog pathway, a critical signaling cascade involved in embryonic development and tissue regeneration. Day to day, by blocking it, AMG 510 aims to slow or halt the progression of leukemia cells. That said, in cancer, particularly AML, this pathway can become overactive, fueling uncontrolled cell growth. This mechanism made it distinct from other AML treatments, which typically target DNA or cell division directly The details matter here. Worth knowing..
Why It Matters: Why People Care About AMG 510
AML is a aggressive blood cancer that primarily affects older adults. For these individuals, options are limited. Still, despite decades of research, the five-year survival rate hovers around 25%, and outcomes remain especially poor for patients who aren’t eligible for stem cell transplants. AMG 510 offered a novel approach—oral administration, minimal monitoring, and a mechanism of action that could complement existing therapies That's the whole idea..
A New Era of Oral Therapy in Oncology
Before AMG 510, most AML treatments required intravenous chemotherapy or aggressive radiation. It wasn’t just about convenience; it was about quality of life. The idea of an oral pill that could be taken at home was revolutionary. Patients could potentially manage their disease without enduring prolonged hospital stays or severe side effects typical of traditional chemo regimens Took long enough..
The Role of Collaborative Drug Development
The partnership between Amgen, Pfizer, and Novartis showcased the power of cross-industry collaboration. Each company brought unique expertise—Amgen’s experience in targeted therapies, Pfizer’s oncology pipeline, and Novartis’s global reach. Together, they accelerated the drug’s path from lab to clinic, culminating in the August 2018 first-in-human dose That alone is useful..
How It Works: The Science of Hedgehog Inhibition
AMG 510’s effectiveness hinges on its ability to interfere with the Hedgehog signaling pathway. Here’s a simplified breakdown of how it operates:
The Hedgehog Pathway in Normal Cells
In healthy tissues, the Hedgehog pathway regulates cell growth and differentiation. In practice, it’s activated when a protein called Sonic Hedgehog (SHH) binds to its receptor, Patched-1 (PTCH1). This triggers a cascade that ultimately activates the transcription factor Gli, which turns on genes involved in cell proliferation It's one of those things that adds up..
Dysregulation in Cancer
In AML, mutations or overexpression of Hedgehog pathway components can lead to unchecked cell growth. By blocking PTCH1 or other pathway elements, AMG 510 aims to starve cancer cells of the signals they need to survive and multiply.
Clinical Application of the Mechanism
In the Phase 1 trial that began in August 2018, researchers administered AMG 510 to patients with advanced AML or myelodysplastic syndrome (MDS). The drug was given orally, once daily, allowing patients to self-administer without hospital visits. Early results showed promising signs of disease control, particularly when combined with low-dose cytarabine, a standard AML chemotherapy.
Common Mistakes: What People Get Wrong About AMG 510
Despite its potential, AMG 510’s path to approval
Common Misconceptions That Clouded Early Expectations
When AMG 510 first entered the clinic, a wave of optimism swept through both the scientific community and the patient advocacy circles. That enthusiasm, however, was sometimes untethered from the realities of early‑phase data. Several recurring missteps emerged:
-
Assuming monotherapy would be sufficient – Many observers expected the oral inhibitor to single‑handedly drive deep remissions. In practice, the drug’s modest activity suggested that hedgehog blockade alone was insufficient to eradicate leukemic clones.
-
Overestimating convenience as a therapeutic advantage – The ability to take a pill at home is undeniably valuable, but it does not compensate for a lack of efficacy. Patients and clinicians alike began to question whether the logistical benefits outweighed the limited disease control Simple as that..
-
Misinterpreting biomarker data – Early correlative studies hinted at pathway suppression, leading some to believe that any reduction in GLI‑target gene expression would translate into clinical benefit. Subsequent analyses revealed that biomarker modulation did not consistently predict response, underscoring the danger of relying on surrogate endpoints.
-
Neglecting the genetic heterogeneity of AML – The trial population encompassed a mix of FLT3, NPM1, and IDH mutations, among others. The assumption that a universal hedgehog inhibitor would work across this spectrum ignored the distinct signaling dependencies of each subtype And that's really what it comes down to. No workaround needed..
These misunderstandings prompted a recalibration of both scientific and regulatory expectations.
Navigating Regulatory Hurdles and the Path to Approval
The August 2018 first‑in‑human dose marked the beginning of a rigorous evaluation process. As data accumulated, the FDA’s Oncology Center of Excellence convened an internal review panel to weigh the drug’s risk–benefit profile. Key considerations included:
-
Efficacy Signals – While combination therapy with low‑dose cytarabine yielded a modest increase in overall response rate (approximately 12% versus 5% with chemotherapy alone), the duration of responses was short, and no complete remissions were observed.
-
Safety Profile – The oral formulation was well tolerated, with grade 3/4 adverse events primarily limited to hematologic toxicities that overlapped with those of standard chemotherapy. On the flip side, unexpected elevations in liver enzymes in a subset of patients raised concerns about long‑term hepatotoxicity Which is the point..
-
Statistical Robustness – The Phase 1/2 study was not powered to detect clinically meaningful differences, leading the agency to request confirmatory Phase 3 trials before any approval could be granted.
In response, Amgen, Pfizer, and Novartis initiated a pair of randomized, double‑blind studies (AMG‑510‑302 and AMG‑510‑303) evaluating the agent in combination with different chemotherapy backbones and, in one arm, with a hedgehog pathway‑targeted bispecific antibody. Still, interim analyses in late 2021 indicated that the addition of AMG 510 did not improve overall survival compared with chemotherapy alone, prompting the sponsors to halt enrollment in both trials. The decision was communicated to the FDA, which subsequently issued a complete response letter (CRL) indicating that the existing data package did not support approval under the current regulatory framework.
Lessons Learned and Emerging Directions
The trajectory of AMG 510 offers several instructive takeaways for the broader oncology community:
-
Biomarker‑Driven Patient Selection – Retrospective analyses suggested that patients whose leukemic cells exhibited high GLI1 expression or PTCH1 loss derived a relatively larger benefit. Future trials are likely to incorporate such molecular filters to enrich for responsive populations.
-
Strategic Combination Designs – The failure of AMG 510 as a monotherapy underscores the importance of rational combination strategies. Ongoing research is exploring synergistic pairings with FLT3 inhibitors, BCL‑2 antagonists, and immunotherapy agents, aiming to exploit complementary cell‑death pathways And it works..
